共 22 条
[1]
Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Kimura M,Ieiri I,Mamiya K,et al. Therapeutic Drug Monitoring . 1998
[2]
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Furuya H,Fernandez-Salguero P,Gregory W,et al. Pharmacogenetics . 1995
[3]
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Aithal GP,Day CP,Kesteven PJ,et al. The Lancet . 1999
[4]
Correlation of human P4502C substrate specificities with primary structure-warfarin as a probe. Kaminsky. LS,de Morais SMF,Faletto MB,et al. Molecular Pharmacology . 1993
[5]
cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Kimura S,Pastewka J,Gelboin HV,et al. Nucleic Acids Research . 1987
[6]
Human hepatic cytochrome P450 catalyzes the rate limiting pathway of torasemide metabolism. Miners JO,Rees DLP,Valenre L,et al. Journal of Pharmacology and Experimental Therapeutics . 1995
[7]
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Sullivan-Klose TH,Ghanayem BI,Bell DA,et al. Pharmacogenetics . 1996
[8]
Inheritance of poor phenytoin parahydroxylation capacity in an Dutch family. Vermeij P,Ferrari MD,Buruma OJ,et al. Clinical Pharmacology and Therapeutics . 1988
[9]
Phenytoin: pharmacogenetic polymorphism of 4 -hydroxylation. Inaba T. Pharmacology and Therapeutics . 1990
[10]
Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4’-hydroxylation activities in livers of Japanese and Caucasian Populations. Inoue K,Yamazaki H,Imiya K,et al. Pharmacogenetics . 1997